[Pharmaceutical prior authorization: real need or computerized antiquity?].
作者信息
Hernández Rodríguez Miguel Ángel, Orueta Sánchez Ramón
出版信息
Aten Primaria. 2013 Feb;45(2):81-3. doi: 10.1016/j.aprim.2013.01.003.
Abstract
摘要
相似文献
1
[Pharmaceutical prior authorization: real need or computerized antiquity?].
Aten Primaria. 2013 Feb;45(2):81-3. doi: 10.1016/j.aprim.2013.01.003.
2
Electronic Prior Authorization for Prescription Drugs - Challenges and Opportunities for Reform.
N Engl J Med. 2023 Mar 9;388(10):867-870. doi: 10.1056/NEJMp2214620. Epub 2023 Mar 4.
3
Prior authorization for safety, not just for economy.
Manag Care. 2012 Dec;21(12):33-5.
4
Electronic Prior Authorization Is Here: What You Need to Know About It.
Minn Med. 2016 Mar-Apr;99(2):44-6.
5
[Validation inspection of prescription drugs in Spain: current situation from a health professional perspective after its introduction in electronic form].
Aten Primaria. 2013 Feb;45(2):74-81. doi: 10.1016/j.aprim.2012.09.002. Epub 2012 Nov 11.
6
Reducing the prescribing of heavily marketed medications: a randomized controlled trial.
J Gen Intern Med. 2009 Aug;24(8):897-903. doi: 10.1007/s11606-009-1013-x. Epub 2009 May 28.
7
Towards creating the perfect electronic prescription.
J Am Med Inform Assoc. 2015 Apr;22(e1):e7-e12. doi: 10.1136/amiajnl-2014-002738. Epub 2014 Jul 18.
8
Final Notice.
N Y State Dent J. 2016 Jan;82(1):15-6.
9
Using patients to promote evidence-based prescribing: comment on "Communicating uncertainties about prescription drugs to the public".
Arch Intern Med. 2011 Sep 12;171(16):1468-9. doi: 10.1001/archinternmed.2011.369.
10
Prescription drugs that are not dispensed.
Tidsskr Nor Laegeforen. 2020 Sep 28;140(13). doi: 10.4045/tidsskr.19.0577. Print 2020 Sep 29.
引用本文的文献
1
[The family doctor and the barriers to prescribing the new oral anticoagulants: Heterogeneity, inequality and confusion. Statement of the Spanish Primary Care and Family Medicine Societies].
Aten Primaria. 2014 Jan;46(1):1-3. doi: 10.1016/j.aprim.2013.10.001. Epub 2013 Nov 21.
本文引用的文献
1
Availability of comparative efficacy data at the time of drug approval in the United States.
JAMA. 2011 May 4;305(17):1786-9. doi: 10.1001/jama.2011.539.
2
Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22. doi: 10.18553/jmcp.2010.16.1.15.
3
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
N Engl J Med. 2008 Oct 23;359(17):1802-10. doi: 10.1056/NEJMsa0803410.
4
Impact of pharmaceutical prior authorisation policies : a systematic review of the literature.
Pharmacoeconomics. 2007;25(8):637-48. doi: 10.2165/00019053-200725080-00002.
5
Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
Br J Clin Pharmacol. 2007 Feb;63(2):159-62. doi: 10.1111/j.1365-2125.2006.02812.x. Epub 2006 Dec 7.
6
Effect of a prior authorization process on antiplatelet therapy and outcomes in patients prescribed clopidogrel following coronary stenting.
Can J Cardiol. 2006 Dec;22(14):1205-8. doi: 10.1016/s0828-282x(06)70960-6.
7
[Inspection validation of prescription: guaranteeing proper use of medicines or a cost-control measure?].
Aten Primaria. 2006 Mar 31;37(5):278-86. doi: 10.1157/13086315.
Zotero 插件